Drug Trial Radar · NCT03659058
Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
Last checked: Nov 20, 2026Latest source record: Nov 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Mar 2, 2016
Primary completion
Aug 2018
Study completion Aug 1, 2018
Sponsor
- Lead sponsor
- Zagazig UniversityGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Sep 6, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
with the introduction of Direct-acting antiviral agents in the management of HCV, the scope of inclusion criteria had been widened to include patients with compensated cirrhosis and even in special situations patients with decompensated liver disease; a chance that was not offered by the limited and strict inclusion criteria needed for treatment by pegylated interferon-based regimen. this made the number of patients with progressive liver fibrosis of cirrhosis had been inv=creased even after achieving SVR. the debate about the impact of SVR on halting fibrosis progression had risen; some studies postulated that patients benefit from an SVR through reduction of mortality, morbidity, and improved quality of life ; however, some patients may maintain their level of fibrosis or even progress to cirrhosis despite achieving SVR and the risk for HCC remains even after virologic eradication.
Conditions
- Fibrosis, Liver
Interventions
silymarinDrug
silymarin 140 three times daily
Ursodeoxycholic AcidDrug
Ursodeoxycholic Acid 500
AntioxidantsDrug
Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
ColchicineDrug
Colchicine 0.6
FOLLOW UPOther
follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in liver stiffness measurement by FibroscanTime frame: 1 year
- Improved portal hypertension parametersTime frame: 1 year
- Improved splenic stiffness measurementTime frame: 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.